• John J V McMurray, Justin A Ezekowitz, Basil S Lewis, Bernard J Gersh, Sean van Diepen, John Amerena, Jozef Bartunek, Patrick Commerford, Byung-Hee Oh, Veli-Pekka Harjola, Sana M Al-Khatib, Michael Hanna, John H Alexander, Renato D Lopes, Daniel M Wojdyla, Lars Wallentin, Christopher B Granger, and ARISTOTLE Committees and Investigators.
• BHF Cardiovascular Research Centre, University of Glasgow, Glasgow, Scotland, United Kingdom. john.mcmurray@glasgow.ac.uk
• Circ Heart Fail. 2013 May 1; 6 (3): 451-60.

BackgroundWe examined the risk of stroke or systemic embolism (SSE) conferred by heart failure (HF) and left ventricular systolic dysfunction (LVSD) in the Apixaban for Reduction in Stroke and Other Thromboembolic Events in Atrial Fibrillation Trial (ARISTOTLE), as well as the effect of apixaban versus warfarin.Methods And ResultsThe risk of a number of outcomes, including the composite of SSE or death (to take account of competing risks) and composite of SSE, major bleeding, or death (net clinical benefit) were calculated in 3 patient groups: (1) no HF/no LVSD (n=8728), (2) HF/no LVSD (n=3207), and (3) LVSD with/without symptomatic HF (n=2736). The rate of both outcomes was highest in patients with LVSD (SSE or death 8.06; SSE, major bleeding, or death 10.46 per 100 patient-years), intermediate for HF but preserved LV systolic function (5.32; 7.24), and lowest in patients without HF or LVSD (1.54; 5.27); each comparison P<0.0001. Each outcome was less frequent in patients treated with apixaban: in all ARISTOTLE patients, the apixaban/warfarin hazard ratio for SSE or death was 0.89 (95% confidence interval, 0.81-0.98; P=0.02); for SSE, major bleed, or death it was 0.85 (0.78-0.92; P<0.001). There was no heterogeneity of treatment effect across the 3 groups.ConclusionsPatients with LVSD (with/without HF) had a higher risk of SSE or death (but similar rate of SSE) compared with patients with HF but preserved LV systolic function; both had a greater risk than patients without either HF or LVSD. Apixaban reduced the risk of both outcomes more than warfarin in all 3 patient groups.Clinical Trial RegistrationURL: http://www.clinicaltrials.gov. Unique identifier: NCT00412984.

31 keywords...

hide…